ADMA 📈 ADMA Biologics - Overview

ADMA Biologics, Inc. is a biopharmaceutical company that specializes in the development, manufacturing, and marketing of plasma-derived biologics, which are used to treat immune deficiencies and infectious diseases. The company's product portfolio includes BIVIGAM and ASCENIV, both of which are intravenous immune globulin (IVIG) products designed to treat primary humoral immunodeficiency (PI), a condition where patients lack sufficient antibodies to fight off infections. Additionally, ADMA Biologics offers Nabi-HB, a product used to treat acute exposure to blood containing Hepatitis B surface antigen, providing a crucial line of defense against this infectious disease.

The company's research and development efforts are focused on expanding its pipeline of plasma-derived therapeutics, with a particular emphasis on products related to the treatment and prevention of S. pneumonia infection. This is a significant area of focus, given the potential for immunoglobulins to provide targeted protection against specific pathogens. By leveraging its expertise in plasma-derived biologics, ADMA Biologics aims to develop innovative solutions that address unmet medical needs in the fields of immunology and infectious disease. The company's commitment to R&D has the potential to drive long-term growth and improve patient outcomes.

From an operational perspective, ADMA Biologics has established a robust infrastructure to support its business. The company operates source plasma collection facilities, which provide a critical source of raw materials for its manufacturing processes. In terms of distribution, ADMA Biologics has established relationships with independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers, enabling it to reach a wide range of customers and patients across the United States and internationally. With its headquarters in Ramsey, New Jersey, the company is well-positioned to navigate the complex regulatory landscape of the biopharmaceutical industry.

As a publicly traded company listed on the NASDAQ stock exchange, ADMA Biologics, Inc. is subject to the usual disclosure requirements and regulatory oversight. The company's common stock is traded under the ticker symbol ADMA, and its ISIN is US0008991046. From a classification perspective, ADMA Biologics is categorized as a biotechnology company, which reflects its focus on developing and commercializing innovative biologic products. With its strong foundation in plasma-derived biologics and its commitment to R&D, the company is poised for continued growth and success in the biopharmaceutical industry.